Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer.
about
Pericyte dynamics during angiogenesis: new insights from new identitiesMyeloid cells contribute to tumor lymphangiogenesisTargeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouseClinicopathological correlation analysis of (lymph) angiogenesis and corneal graft rejectionThe PCa Tumor Microenvironment.Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells.Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.Recruitment and retention: factors that affect pericyte migration.Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse.Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.Pericyte antigens in angiomyolipoma and PEComa family tumors.A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis.RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.Pericyte Antigens in Perivascular Soft Tissue Tumors.Vascular pericyte density and angiogenesis associated with adenocarcinoma of the prostate.Nerve/Glial Antigen 2: A Novel Target for Anti-Tumor Therapy in Colorectal Cancer.
P2860
Q27008071-604F44F6-E943-468E-A218-FB7EE282143FQ27342202-639C91EC-70A1-4892-A53F-39449918AA0DQ33252817-4825DB1D-3ED6-4602-87EB-30D2068FD8C1Q35089344-8E25375F-3877-4B31-8474-F5E93FD43657Q35603143-1435F6F1-B6CB-4CAF-B3A9-C6B895EF8F7BQ36245636-EFE92B79-C558-4B44-999F-B1FBE1ED6007Q36851279-6DD4EB12-1865-4A3C-90AB-44C5E2C05FAAQ37723067-C4C8D62A-70EE-41A8-9D47-DB5480564A08Q38126398-135BAC8A-4758-4AAD-9284-8A8DB8A75FA2Q38769098-6232D6AC-629A-4C5D-B1BF-D11F6D1C6909Q38823747-1AE47AB0-CF2E-4FF9-8806-B6BB2164AEC5Q38989966-E891B0CB-1AAE-44FD-BE29-ADDA0C7E808EQ39051468-C6D46F10-A724-438E-861C-A0BFA0AD1412Q41450925-933063FF-3CCB-4C5D-A138-1BE1BB5D6E7BQ42617970-1E3EFAA1-ED12-4647-BF1E-B52B59E12337Q45755546-9AA8AAC5-E068-4518-8ADA-B28B6D0C3935Q53158899-516D8751-456C-4650-AF18-8E2B0E719CE5
P2860
Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@ast
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@en
type
label
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@ast
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@en
prefLabel
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@ast
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@en
P2860
P921
P356
P1433
P1476
Targeting of pericytes diminis ...... giogenesis in prostate cancer.
@en
P2093
Ugur Ozerdem
P2860
P304
P356
10.1002/PROS.20346
P577
2006-02-01T00:00:00Z